00:00 / 00:00
ALPHA-GLUCOSIDASE INHIBITORS | ||
DRUG NAME | acarbose (Precose), miglitol (Glyset) | |
CLASS | Alpha-glucosidase inhibitors | |
MECHANISM OF ACTION | Inhibit alpha-glucosidase enzyme in the small intestine → delay absorption of ingested carbohydrates → smaller rise in blood glucose | |
INDICATIONS |
| |
ROUTE(S) OF ADMINISTRATION |
| |
SIDE EFFECTS |
| |
CONTRAINDICATIONS AND CAUTIONS |
|
NURSING CONSIDERATIONS: ALPHA-GLUCOSIDASE INHIBITORS | ||
ASSESSMENT AND MONITORING | Assess
Monitor
Evaluate
| |
CLIENT EDUCATION |
|
Alpha-glucosidase inhibitors are medications primarily used to treat type 2 diabetes mellitus, and have an unlabeled use for type 1 diabetes mellitus as an adjunct to insulin.
Now, type 2 diabetes mellitus is characterized by insulin resistance, which is when tissue cells have trouble responding to insulin to use glucose from the blood, while in type 1 diabetes mellitus, there’s no insulin at all.
As a result, tissue cells starve for energy despite having high blood glucose levels, which is called hyperglycemia.
Now, alpha-glucosidase inhibitors include medications like acarbose and miglitol, which can be taken orally.
Once administered, these medications act in the small intestine, where they inhibit the enzyme alpha-glucosidase, which helps digest complex carbohydrates into simple carbohydrates, such as glucose, that can be absorbed through the lining of the intestine and into the blood.
As a result, alpha-glucosidase inhibitors delay the absorption of ingested carbohydrates, ultimately leading to a smaller rise in blood glucose.
Unfortunately, the undigested carbohydrates remain within the intestines and are digested by intestinal bacteria.
Because of that, clients taking alpha-glucosidase can often present with gastrointestinal side effects, such as abdominal pain, flatulence, and diarrhea. In addition, acarbose may lead to hepatic injury, while clients on miglitol may develop a skin rash.
As far as contraindications go, alpha-glucosidase inhibitors should not be given to clients with gastrointestinal conditions like inflammatory bowel disease, or IBD for short, as well as ileus, colonic ulceration, or intestinal obstruction.
Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.